1. Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates
- Author
-
Pelayo Correa, D.M. Young, Dan W. Dalgard, Richard H. Adamson, and Susan M. Sieber
- Subjects
Pharmacology ,Cardiotoxicity ,Leukemia ,Time Factors ,Heart Diseases ,business.industry ,Myocardium ,General Medicine ,Haplorhini ,Cercopithecus ,medicine.disease ,Macaca mulatta ,Leukemogenic ,carbohydrates (lipids) ,Macaca fascicularis ,Bone Marrow ,Doxorubicin ,Heart failure ,polycyclic compounds ,medicine ,Animals ,business ,Carcinogen - Abstract
10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg). 8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man. Histologically, the myocardial lesions resembled those found in human anthracycline-induced cardiomyopathy. 1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug. Our results suggest that adriamycin is a more potent cardiotoxin in monkeys than in man, and that leukemia may be a consequence of prolonged treatment with this drug.
- Published
- 1980